Original document(8 pages) Authorized document(8 pages) 中文版
    The present invention relates to a Chinese medicine emplastrum matrix which can be added into Chinese medicine extract and its preparation technique. Said matrix is made up by mixing polyacrylic acid, glycerine, triethanolamine, magnesium hydroxide, polyvinylpyrrolidone, azone and water. Said matrix has large medicine-carrying quantity, unique slowly-releasing process, strong transdermal effect, good breathing property and good affinity with various medicines and skin. Said invented matrix is suitable for making Chinese medicine emplastrum, and is an ideal transdermal administration transferring platform.
Application Number
申请号		 200310105804 Application Date
申请日		 2003.10.08
Title 名称 Chinese medicine cataplasm matrix and preparing technique thereof
Publication Number
公开号		 1528270 Publication Date
公开日		 2004.09.15
Approval Pub. Date Granted Pub. Date 2005.08.24
International Classification 分类号 A61K9/06,A61K47/32
Applicant(s) Name
申请人		 Qianhe Pharmaceutical LLC, Xi'an
Address 地址 710075
Inventor(s) Name 发明人 Ren Jianguo
Attorney & Agent 代理人 he ye

  
Driving state monitor
External use medical ointment for treating mainly rheumatic arthritis
Superfine fresh bone powder and its production process and use
Process for preparing lead cyanamide
Medicine for treating coronary disease and stenocardia and its preparation method
Preparation process of lithium aluminium hydride reduction
Golden silver wire protection layer for paint and its preparation method
Method for preparing anode material of lithium-iron disulphide battery
Method for implementing general soft gateway of dynamic self-adaptive Radius system
Optical fibre winding disk for low water peak treatment
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.